A$1.03 -0.0 -1.9%
Last Trade - 18/06/21
| Market Cap | £167.7m |
| Enterprise Value | £-425.9m |
| Revenue | £496.7m |
| Position in Universe | 523rd / 1914 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 511.2 | 1,109 | 1,150 | 21.9 | 31.0 | +50.0% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Aroa Biosurgery Limited is a New Zealand-based soft tissue repair company. The Company is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. It designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
| Last Annual | March 31st, 2020 |
| Last Interim | September 30th, 2020 |
| Incorporated | September 21, 2007 |
| Public Since | July 24, 2020 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P/ASX All Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 300,074,925 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 2 Kingsford Smith Place Airport Oaks, AUCKLAND, 2022, New Zealand |
| Web | http://aroabio.com/ |
| Phone | +64 9 8693035 |
| Contact | () |
| Auditors | BDO Auckland |
As of 18/06/21, shares in Aroa Biosurgery are trading at A$1.03, giving the company a market capitalisation of £167.7m. This share price information is delayed by 15 minutes.
Shares in Aroa Biosurgery are currently trading at A$1.03 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aroa Biosurgery price has moved by % over the past year.
Of the analysts with advisory recommendations for Aroa Biosurgery, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aroa Biosurgery is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aroa Biosurgery is scheduled to issue upcoming financial results on the following dates:
Aroa Biosurgery does not currently pay a dividend.
Aroa Biosurgery does not currently pay a dividend.
Aroa Biosurgery does not currently pay a dividend.
To buy shares in Aroa Biosurgery you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Aroa Biosurgery are currently trading at A$1.03, giving the company a market capitalisation of £167.7m.
Here are the trading details for Aroa Biosurgery:
Based on an overall assessment of its quality, value and momentum, Aroa Biosurgery is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Aroa Biosurgery are currently priced at A$1.03. At that level they are trading at 93.27% discount to the analyst consensus target price of 0.00.
Analysts covering Aroa Biosurgery currently have a consensus Earnings Per Share (EPS) forecast of -0.0368820166 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aroa Biosurgery. Over the past six months, the relative strength of its shares against the market has been -15.01%. At the current price of A$1.03, shares in Aroa Biosurgery are trading at -14.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Aroa Biosurgery.
We were unable to find the directors for Aroa Biosurgery.
Here are the top five shareholders of Aroa Biosurgery based on the size of their shareholding:
